Children and teenagers (under the age of 18)
A drug Paroxetine Do not use in children and adolescents under 18 years of age.
Treatment with antidepressants for children and adolescents with major depressive disorder and other mental illnesses is associated with an increased risk of suicidal thoughts and suicidal behavior. In clinical trials, adverse reactions associated with suicidal attempts and suicidal thoughts, hostility (mainly aggression, deviant behavior and anger) were more common in children and adolescents who received paroxetine, than in patients of this age group who received a placebo. At present, there is no data on the long-term safety of paroxetine for children and adolescents, which would affect the effect of this drug on growth, maturation, cognitive and behavioral development.
Clinical deterioration and suicidal risk in adults
Young patients, especially those suffering from major depressive disorder, may be at increased risk of suicidal behavior during paroxetine therapy. An analysis of placebo-controlled studies in adults with mental illnesses indicates an increase in the incidence of suicidal behavior in young patients (aged 18-24 years) when taking paroxetine compared to the placebo group (2.19% to 0.92%, respectively ), although this difference is not considered statistically significant. In patients of older age groups (25 to 64 years and older than 65 years), there was no increase in the incidence of suicidal behavior. In adults of all age groups suffering from major depressive disorder, there was a statistically significant increase in cases of suicidal behavior against paroxetine compared with the placebo group (the incidence of suicidal attempts: 0.32% to 0.05%, respectively). However, most of these cases, when taking paroxetine (8 of 11), were registered in young patients aged 18 to 30 years. Data obtained in the study in patients with major depressive disorder,may indicate an increase in the incidence of suicidal behavior in young patients, which may persist in patients older than 24 years with various psychiatric disorders. In patients with depression, the exacerbation of symptoms of this disorder and / or the appearance of suicidal thoughts and suicidal behavior (suicidal) can be observed regardless of whether they receive antidepressants. This risk persists until a pronounced remission is achieved. Improvement of the patient's condition may be absent in the first weeks of treatment or more, and therefore, the patient's condition should be carefully monitored in order to detect clinical exacerbation and suicidality in a timely manner, especially at the beginning of the course of treatment, as well as during periods of dose changes, whether they increase or decrease. Clinical experience with the use of all antidepressants shows that the risk of suicide may increase in the early stages of recovery. Other mental disorders for which treatment is used paroxetine, too, may be associated with an increased risk of suicidal behavior.In addition, these disorders can be comorbid conditions associated with a major depressive disorder. Therefore, in treating patients suffering from other mental disorders, the same precautions should be followed as in the treatment of major depressive disorder.
The greatest risk of suicidal ideation or suicide attempts is patients with a history of suicidal behavior or suicidal thoughts, young patients, and patients with severe suicidal thoughts prior to treatment, and therefore all need to be given special attention during treatment. Patients (and those who care for them) should be warned about the need to monitor their deterioration (including the development of new symptoms) and / or the appearance of suicidal thoughts / suicidal behavior or thoughts of self-harm during the course of treatment, especially at the beginning of treatment , during the change in the dose of the drug (increase and decrease). If these symptoms occur, seek medical help immediately.
It should be remembered that such symptoms as agitation, akathisia or mania may be associated with a major disease or be a consequence of the therapy used. If symptoms of clinical impairment (including development of new symptoms) and / or suicidal thoughts / behavior occur, especially if they suddenly appear, the severity of the manifestations increases, or if they are not part of the previous symptom complex in this patient, before drug cancellation.
Akathisia
Occasionally, treatment with paroxetine or another SSRI drug is accompanied by the appearance of akathisia, which is manifested by a feeling of inner anxiety and psychomotor agitation, when the patient can not sit or stand still; At akathisia the patient usually experiences subjective discomfort. The likelihood of akathisia is highest in the first few weeks of treatment.
Serotonin syndrome / malignant neuroleptic syndrome
In rare cases, against the background of paroxetine treatment, serotonin syndrome or symptomatology like a malignant neuroleptic syndrome may occur,especially if paroxetine are used in combination with other serotonergic drugs and / or antipsychotics. These syndromes pose a potential threat to life, and therefore treatment with paroxetine should be discontinued if they occur (they are characterized by groups of symptoms such as hyperthermia, muscle rigidity, myoclonus, autonomic disorders with possible rapid changes in vital signs, changes in mental status, including confusion consciousness, irritability, extremely hard agitation, progressing to delirium and coma), and begin supporting symptomatic therapy. Paroxetine should not be used in combination with serotonin precursors (such as L-tryptophan, oxytryptan) due to the risk of developing serotonergic syndrome.
Mania and bipolar disorder
A major depressive episode may be the initial manifestation of bipolar disorder. It is generally accepted (although not proven by controlled clinical trials) that treating such an episode with an antidepressant alone may increase the likelihood of an accelerated development of a mixed / manic episode in patients at risk of bipolar disorder.Before starting treatment with an antidepressant, a thorough screening should be performed to assess the risk of a bipolar disorder in the patient; such screening should include the collection of a detailed psychiatric history, including data on the presence in the family of cases of suicide, bipolar disorder and depression. Paroxetine It is not registered for the treatment of a depressive episode in the context of bipolar disorder. Paroxetine should be used with caution in patients who have a history of mania.
Diabetes
In patients with diabetes mellitus, treatment with SSRIs may affect glycemic control. You may need to adjust the dose of insulin and / or oral hypoglycemic drugs.
MAO inhibitors
Treatment with paroxetine should be started cautiously no earlier than 2 weeks after discontinuation of therapy with MAO inhibitors; The dose of paroxetine should be increased gradually until an optimal therapeutic effect is achieved.
Impaired kidney or liver function
It is advisable to use caution in treating paroxetine in patients with severe renal impairment or in patients with impaired hepatic function.
Epilepsy
Like other antidepressants, paroxetine should be used with caution in patients with epilepsy.
Convulsive seizures
Frequency of convulsive seizures in patients taking paroxetine, is less than 0.1%. In the event of a seizure, paroxetine should be discontinued.
Electroconvulsive therapy
There is only limited experience in the simultaneous use of paroxetine and electroconvulsive therapy.
Glaucoma
Like other SSRIs, paroxetine may cause mydriasis, and it should be used with caution in patients with closed-angle glaucoma.
Hyponatremia
In the treatment of paroxetine, hyponatremia occurs rarely and predominantly in elderly patients and is leveled after the withdrawal of paroxetine.
Bleeding
Hemorrhages in the skin and mucous membranes (including gastrointestinal and gynecological bleeding) have been reported in patients with paroxetine. therefore paroxetine Caution should be used with caution in patients who simultaneously receive drugs that increase the risk of bleeding in patients with a known tendency to bleeding and patients with diseases predisposing to bleeding.
Heart Disease
In the treatment of patients with heart disease, the usual precautionary measures should be observed.
Symptoms that may occur when discontinuing paroxetine treatment in adults
According to clinical studies in adults, the incidence of adverse reactions with paroxetine was 30%, while the incidence of adverse reactions in the placebo group was 20%. The onset of withdrawal symptoms does not mean that the drug is abused or addictive, as is the case with drugs and psychotropic substances. Describing withdrawal symptoms such as dizziness, sensory disturbances (including paresthesia, electric shock and tinnitus), sleep disorders (including bright dreams), agitation or anxiety, nausea, tremors, confusion, increased sweating, headaches and diarrhea , palpitations, emotional lability, irritability and visual disturbances. Usually these symptoms are mild or moderate, but in some patients they can be severe. Usually, they occur in the first few days after the drug is discontinued, but in very rare cases there are patients who accidentally missed taking only one dose.As a rule, these symptoms pass spontaneously and disappear within 2 weeks, but in some patients they can last much longer (2-3 months or more). It is recommended to reduce the dose of paroxetine gradually, for several weeks or months before its complete cancellation, depending on the needs of the individual patient.
Symptoms that may occur when paroxetine is discontinued in children and adolescents
As a result of clinical studies in children and adolescents, the incidence of adverse reactions with paroxetine withdrawal was 32%, while the incidence of adverse reactions in the placebo group was 24%. Symptoms of paroxetine withdrawal (emotional lability, including suicidal thoughts, suicidal attempts, mood changes and tearfulness, as well as nervousness, dizziness, nausea and abdominal pain) were recorded in 2% of patients on the background of a decrease in the dose of paroxetine or after its complete withdrawal and were 2 times more common than in the placebo group.
Fractures of bones
Based on the results of epidemiological studies of the risk of bone fractures, bone fragility was associated with the use of antidepressants, including SSRIs.The risk was observed during the course of treatment with antidepressants and was the maximum at the beginning of the course of therapy. The possibility of bone fractures should be considered when using paroxetine.
Tamoxifen
Some studies have shown that the effectiveness of tamoxifen, measured as the ratio of breast cancer recurrence / lethality, decreases with co-administration with paroxetine, as a result of irreversible inhibition of the isoenzyme CYP2D6. Risk can increase with joint application for a long time. When tamoxifen is used to treat or prevent breast cancer, consideration should be given to the use of alternative antidepressants that do not inhibit the isoenzyme CYP2D6 or render it to a lesser extent.